Catherine Stehman-Breen is a Venture Partner at F-Prime based in Boston, focusing on new company creation. She has more than 30 years of medical and biopharmaceutical experience. Prior to joining F-Prime, Catherine was CEO of Chroma Medicine, a company developing a novel epigenetic editing therapeutics platform where she built the company from inception. Previously, she was Chief Research and Development Officer at Obsidian Therapeutics, a cell therapy company developing engineered tumor infiltrating lymphocyte therapies for patients with solid tumors. As Entrepreneur in Residence at Atlas Venture, she worked closely with start-ups across a range of technologies and previously served as Chief Medical Officer at Sarepta Therapeutics. In addition, Catherine held various leadership roles at Regeneron and Amgen.

Catherine earned her M.D. from the University of Chicago. She completed her residency and nephrology fellowship training at the University of Washington, where she also received an M.S. in epidemiology. Catherine served as a faculty member in the division of nephrology and remains an affiliate associate professor in the University of Washington School of Public Health, with more than 90 publications in medical journals.